# EPO906 Therapy in Patients With Advanced Melanoma

> **NCT00035165** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 51 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** epothilone b

## Key facts

- **NCT ID:** NCT00035165
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** 2003-05
- **Final completion:** —
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2012-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00035165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00035165, "EPO906 Therapy in Patients With Advanced Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00035165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*